Chinese study links prenatal organophosphate ester exposure to altered pregnancy glucose

Every sofa, car seat, laptop charger, and crib mattress owes much of its fire resistance to a family of chemicals that scientists are now tracking deep into human metabolism. Organophosphate esters, or OPEs, quietly replaced older flame retardants that were phased out over health concerns, and they have inherited those concerns along with the market. A new study published in Frontiers of Environmental Science & Engineering by researchers at the Shanghai Institute for Biomedical and Pharmaceutical Technologies and collaborating institutions reports that these compounds, absorbed by pregnant women at ordinary background levels, are associated with measurable shifts in blood glucose during gestation. Drawing on the Shanghai-Minhang Birth Cohort Study, the team found that the heaviest exposure to certain OPE metabolites coincided with lower fasting glucose, while moderate exposure appeared to push one-hour glucose upward—a puzzling, non-linear signature suggesting that the chemicals may interfere with the delicate hormonal recalibration that every pregnancy demands.

To understand why the finding matters, it helps to know what OPEs are and how pervasive they have become. Organophosphate esters are synthetic compounds built around a central phosphorus atom bonded to oxygen and to variable organic side chains—chlorinated alkyl groups in flame retardants such as tris(1,3-dichloro-2-propyl) phosphate, or aryl groups in plasticizers such as triphenyl phosphate. Because they are typically added to materials rather than chemically bonded into them, they migrate out of polyurethane foams, plastics, textiles, electronic housings, and building materials into indoor air and dust. Humans inhale, ingest, and absorb them through the skin, and reviews have documented the compounds in foodstuffs, lake sediments, and marine environments worldwide. Once inside the body, enzymes cleave the ester bonds, and the resulting metabolites—dialkyl and diaryl phosphates such as bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), dibutyl phosphate (DBP), and diphenyl phosphate (DPHP)—circulate briefly and exit in urine. That urinary fingerprint is what epidemiologists use to reconstruct a person’s recent exposure.

The new analysis rests on that biomarker approach within the Shanghai-Minhang Birth Cohort Study, a long-running effort following mothers and children in a densely populated urban district of China. Between gestational weeks 12 and 16—a window that falls before the classical surge of pregnancy-induced insulin resistance—the researchers collected urine samples and measured concentrations of eight OPE metabolites. They then mined medical records for two glucose indices routinely assessed in prenatal care: fasting plasma glucose, or FPG, drawn after an overnight fast, and one-hour plasma glucose, or 1 h-PG, captured during the oral glucose tolerance test that screens for gestational diabetes mellitus, known as GDM. Women were classified as having elevated glucose levels if they displayed abnormal fasting values, abnormal one-hour values, or a clinical GDM diagnosis. This design allowed the team to ask not simply whether exposure was linked to disease, but whether OPE burdens tracked with continuous glucose readings across the normal-to-abnormal spectrum.

Analytically, the researchers deployed three complementary statistical engines. Multiple linear regression estimated how each individual metabolite related to glucose concentrations while adjusting for potential confounders. Modified Poisson regression—a technique favored for common binary outcomes because it yields interpretable risk ratios—tested whether exposure raised the probability of landing in the elevated-glucose category. Most notably, the team applied Bayesian Kernel Machine Regression, or BKMR, a flexible machine-learning framework built for environmental-health mixtures, in which people carry dozens of correlated chemicals at once. BKMR sidesteps the collinearity problems that plague conventional regression by estimating the joint effect of the mixture and ranking each component’s relative contribution. Urinary metabolites were also grouped into exposure categories, allowing comparisons between the lowest and highest strata for each compound and for the summed chlorinated-OPE class, ΣCl-OPEs—the subgroup toxicologists watch most closely because chlorinated OPEs are persistent, abundant in indoor environments, and increasingly implicated in metabolic disruption.

The results refused to follow a simple dose-response script. Compared with women in the lowest exposure group, those with the highest exposure to BDCIPP, dibutyl phosphate, and diphenyl phosphate showed significantly lower fasting plasma glucose. On its face, a glucose-lowering signal might sound benign, even welcome. But endocrine disruption rarely works that way. Fasting glucose is governed largely by hepatic glucose output and basal insulin secretion, and both abnormally high and abnormally low values can mark metabolic trouble: impaired fasting glucose, as diabetes researchers have long established, involves defects in how the liver handles glucose overnight, while low fasting glucose in pregnancy raises its own concerns. A downward shift in FPG among the most exposed women suggests these chemicals are not passive passengers in maternal metabolism but active perturbers of glucose homeostasis—possibly by altering insulin sensitivity, pancreatic beta-cell performance, or liver signaling in ways that standard toxicology has yet to map.

The one-hour picture looked strikingly different. Rather than falling at high exposures, 1 h-PG tended to rise in the moderate exposure group, with the summed chlorinated-OPE metabolites showing a marginally significant positive association. Modified Poisson models echoed the pattern: women with moderate exposure carried an increased risk of being classified with elevated glucose levels—driven by abnormal screening values or a GDM diagnosis—although the estimate did not reach statistical significance. This inverted-U shape, in which middle doses show effects that the extremes do not, is a recognized hallmark of endocrine-active chemicals, whose actions often depend on receptor occupancy, hormone feedback loops, and nonlinear cellular responses rather than the monotonic dose-response assumed in classical toxicology. It also complicates regulation, which is typically built on the assumption that more exposure means more harm. Here, the middle of the exposure distribution appeared to carry the heaviest burden for post-challenge glucose—the metric most closely tied to how efficiently the body clears a glucose load.

Because pregnant women carry chemical mixtures rather than single compounds, the BKMR analysis offered the study’s sharpest lens. The model pointed to chlorinated OPEs as the primary contributors to the observed glucose changes. For fasting glucose, bis(1,3-dichloro-2-propyl) phosphate emerged as the dominant driver; for the one-hour reading, it was bis(1-chloro-2-propyl) phosphate, or BCIPP, the breakdown product of tris(1-chloro-2-propyl) phosphate. Both parent flame retardants are workhorse chlorinated OPEs embedded in flexible polyurethane foam—the stuffing inside sofas, mattresses, and car seats—and both are routinely detected in household dust and human urine across Europe, North America, and Asia. The convergence on the chlorinated class aligns with earlier evidence: a 2024 case-control study in Environmental Science & Technology identified specific OPEs contributing to heightened gestational diabetes risk, and research on older Chinese adults has linked OPE exposure with insulin resistance and glycometabolic disorders. The Shanghai cohort extends that signal into a critical early-pregnancy window.

One of the study’s most intriguing threads concerns what the women ate. The inverse associations between OPE exposure and fasting glucose appeared predominantly among pregnant women who consumed fruits and vegetables daily. The researchers point toward a plausible mechanism: dietary antioxidants. Fruits and vegetables deliver vitamins C and E, carotenoids, and polyphenols that quench the reactive oxygen species implicated in pancreatic beta-cell damage, and oxidative stress is a documented mediator of beta-cell dysfunction. Experimental work on related plasticizers such as phthalates has shown antioxidant vitamins blunting insulin resistance in animal models, and nutrition research has independently linked high dietary fiber and low glycemic load to reduced gestational diabetes risk. If antioxidant-rich diets buffer the metabolic stress generated by flame retardant metabolites, that would point to a modifiable lever—although the observational design cannot yet separate a true protective interaction from differences in overall diet quality, supplement use, or the broader health consciousness of women who eat produce every day.

Pregnancy supplies the biological backdrop that makes these findings consequential. From the second trimester onward, placental hormones—human placental lactogen, progesterone, prolactin, and placental growth hormone—deliberately induce insulin resistance in the mother, diverting glucose toward the fetus while the maternal pancreas compensates by expanding insulin secretion. Gestational diabetes arises when beta-cells cannot keep pace with this hormonal challenge, and hyperglycemia at almost any level, as the landmark HAPO study demonstrated, increases the risks of excessive fetal growth, birth complications, and later metabolic disease for both mother and child. OPEs offer several candidate pathways into this system: they have been associated with urinary oxidative stress biomarkers in exposed populations, and data-driven and laboratory analyses have tied replacement flame retardants to lipid metabolic disorder pathways. The placenta, which orchestrates the entire metabolic shift, expresses enzymes and transporters that these compounds can engage, making pregnancy a period when even modest endocrine interference may ripple through both maternal and fetal physiology.

The authors are careful about what their study can and cannot show. It is observational, it relies on a single urine measurement in early pregnancy that may not capture exposure across gestation, and several signals—the moderate-exposure glucose elevations and the elevated-glucose risk ratios—were only marginally significant or statistically inconclusive. Reverse causation remains conceivable, since glucose metabolism influences hydration, diet, and kidney clearance, all of which shape urinary metabolite concentrations. Still, the study’s strengths—a prospective cohort framework, validated exposure biomarkers, mixture-based modeling, and the triangulation of three independent statistical approaches—make it a meaningful addition to a fast-growing literature on substitute flame retardants and metabolic health. Practically, the message cuts both ways. Chlorinated OPEs are nearly impossible for individuals to avoid, saturating dust, food, and everyday goods, which places the burden of response on chemical policy and product design rather than on pregnant women themselves. Meanwhile, the fruit-and-vegetable signal, however preliminary, reinforces a familiar prescription. As flame retardants continue their quiet circulation through homes and bodies, this study suggests the glucose fluctuations they leave behind deserve far louder attention.